Navigation Links
Vidaza Significantly Extends Overall Survival by 74% in Phase 3 Trial in Myelodysplastic Syndromes (MDS)
Date:8/19/2007

Two year survival rate of 50.8 percent for Vidaza versus 26.2 for

conventional care regimens 9.4 months median survival benefit for patients on Vidaza compared to

conventional care regimens Only agent to demonstrate survival benefit in MDS compared to conventional

care regimens

Only epigenetic modifier to show survival benefit in cancer

Stratified log-rank p-value = 0.0001, Hazard ratio = 0.58

Largest study ever conducted in higher-risk MDS

BOULDER, Colo., Aug. 2 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM) today announced topline results from the multi-institutional, international, randomized, Phase 3 controlled trial of Vidaza(R) (azacitidine for injection) versus conventional care regimens (CCR) in the treatment of patients with higher-risk myelodysplastic syndromes (MDS). In the primary endpoint analysis, Vidaza treatment was associated with a median survival of 24.4 months versus 15 months for those receiving CCR treatment, an improvement of 9.4 months with a stratified log-rank p-value of 0.0001. The hazard ratio describing this treatment effect was 0.58 (95 percent confidence interval of 0.43 to 0.77). Two-year survival rates were 50.8 percent versus 26.2 percent for patients receiving Vidaza versus CCR (p<0.0001). Median number of treatment cycles was nine for Vidaza.

The survival benefits of Vidaza were consistent regardless of the CCR treatment option (best supportive care (BSC) alone, low-dose cytarabine plus BSC or standard chemotherapy plus BSC) utilized in the control arm.

"These landmark results, showing a significant improvement in survival
'/>"/>

SOURCE Pharmion Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
2. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
3. Arterial Plaque Significantly Reduced in Women Age 50-59 Taking Hormones, Says New Analysis of Womens Health Initiative Data
4. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
5. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
6. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
7. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
8. Ivivis PEMF Technology Significantly Improves Neuron Survival in Parkinsons Disease Model, Study Finds
9. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
10. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
11. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 ApolloDx™ today announced it ... during a special event at the company,s office in ... September 5, 2014. The event, which will start at ... website, www.apollodx.com .    "We believe ... Jared Bauer , Co-Founder and Managing Partner of ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Market for Medical ... The European, Middle Eastern and African markets ... As part of its coverage, this study: The ... the EMEA medical device markets and estimates markets ...
(Date:8/20/2014)... -- Reportlinker.com announces that a new market research ... Global Patient Scales Industry ... worldwide markets for Patient Scales in US$ Thousand ... & Baby Scales, Chair Scales, and Under Bed ... the US, Canada, Japan, Europe, Asia-Pacific, Latin America, ...
Breaking Medicine Technology:The Market for Medical Devices in EMEA 2The Market for Medical Devices in EMEA 3The Market for Medical Devices in EMEA 4The Market for Medical Devices in EMEA 5Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19
... July 12, 2011 Imagenetix, Inc. (OTCBB: IAGX) issued today a ... 31, 2011 and its focus for the future. ... fiscal year ended March 31, 2011 and as we commence the ... and summarize our strategic focus for the future.   ...
... July 12, 2011 Roche (SIX: RO, ROG; ... CALP ) today announced a co-marketing ... protocols for the NimbleGen SeqCap EZ Library solution-based ... collaboration aims to simplify high throughput targeted resequencing ...
Cached Medicine Technology:Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 2Imagenetix, Inc. Discusses March 31, 2011 Fiscal Year End Results and Future Focus 3Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing 2Roche NimbleGen and Caliper Collaborate to Offer Automated Target Enrichment Pipeline Solution for Next-Generation Sequencing 3
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. ... women avoid a condition that causes a life-threatening irregular heartbeat, ... a 10 percent lower risk of developing atrial fibrillation, compared ... Aug. 20 issue of the Journal of the American ... the heart rhythm disorder even if they were obese, the ...
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
(Date:8/20/2014)... to treating kidney failure by removing waste products from ... who suddenly developed the condition, in an analysis led ... Medicine. , Their findings, published online in the journal ... method that is standardly used for people with sudden ... the patient. , "Our findings question the accepted notion ...
(Date:8/20/2014)... August 20, 2014 As concerns regarding ... power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in gynecological surgery ... U.S. Senators from New York are urging the U.S. ... of the devices. In a letter dated August 19th, ... implored the agency to seriously consider the testimony given ...
(Date:8/20/2014)... common cause of endophthalmitis, a potentially blinding condition that ... injections, are the well-known staphylococci ("staph") and ... study published in the August issue of Ophthalmology ... of cases at New York Eye and Ear Infirmary ... found that gram-positive bacteria, which include staph and strep ...
Breaking Medicine News(10 mins):Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:Pitt analysis questions use of acute hemodialysis treatment 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 2Health News:Researchers pinpoint most common causes of dangerous eye infection post surgery and trauma 3
... , , BOULDER, Colo., Aug. ... BOYCOTT WHOLE FOODS. , , elephantjournal.com,s editor Waylon ... times) on the home page of Huffington Post, garnered 500+ comments, ... Camera. , , To read more, please visit: ...
... test may detect peripheral artery disease, research shows , FRIDAY, ... circulation in the ankle could help doctors identify patients at ... The test compares blood flow in the ankle to that ... could suggest that a patient suffers from peripheral artery disease, ...
... flu virus creates a surge of patients during the ... health care workers given their important role in treating ... Protection for Healthcare Workers in the Workplace Against Novel ... of Medicine, recommends the best means to guard health ...
... MUMBAI, India, Aug. 28 Sun Pharmaceutical Industries Ltd. ... today announced that on August 27, 2009, Sun filed a ... the Antitrust Division of the U.S. Department of Justice to ... the Tender Offer by Alkaloida Chemical Company Exclusive Group Ltd. ...
... there,s more than swine flu circulating out there , FRIDAY, ... Kristi Yamaguchi is teaming up with U.S. health experts to ... With all the hype around the H1N1 swine flu, don,t ... This year, like every year, Yamaguchi will be lining up ...
... , REDWOOD CITY, Calif. and SEATTLE, ... FACT ) and Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN ... and commercialization of TRU-016, a product candidate in phase 1 ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20090320/TRUBIONLOGO ) , , ...
Cached Medicine News:Health News:Ankle Circulation Could Warn of Future Strokes 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 2Health News:Sun Pharmaceutical Files HSR Application for Taro Tender Offer 3Health News:Kristi Yamaguchi, Olympic Ice Skater, Pushes Seasonal Flu Shots 2Health News:Kristi Yamaguchi, Olympic Ice Skater, Pushes Seasonal Flu Shots 3Health News:Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016 2Health News:Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016 3Health News:Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016 4Health News:Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016 5Health News:Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016 6
... is ideal for all liquid handling applications ... operating buttons, and various dispensing techniques such ... make this a lab favorite. It intuitively ... pipette without any adverse effects on the ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... The total ergonomic solution and best ... Soft, feather touch action and ultra lightweight ... Stress-free tip ejection with long, lever tip ... identification , Accepts universal tips or for ...
Medicine Products: